| Methods |
2‐week washout; 2‐week single‐blind placebo run‐in; inclusion criteria= mean sitting DBP 95‐114 mm Hg after washout; 4‐week double‐blind treatment |
| Participants |
All candesartan groups: n=185(129 males,56 females); mean age=53 years;
Candesartan 2 mg: baseline sitting SBP=151.7 mm Hg, DBP=102.4 mm Hg;
Candesartan 4 mg: baseline sitting SBP=154.9 mm Hg, DBP=104.0 mm Hg;
Candesartan 8 mg: baseline sitting SBP=152.1 mm Hg, DBP=102.0 mm Hg;
Candesartan 12 mg: baseline sitting SBP=153.4 mm Hg, DBP=103.4 mm Hg;
Candesartan 16 mg: baseline sitting SBP=152.3 mm Hg, DBP=102.4 mm Hg;
Placebo: n=39; baseline sitting SBP=154.6 mm Hg, DBP=103.2 mm Hg |
| Interventions |
Candesartan 2 mg once daily;
Candesartan 4 mg once daily;
Candesartan 8 mg once daily;
Candesartan 12 mg once daily;
Candesartan 16 mg once daily;
Placebo;
taken just before breakfast |
| Outcomes |
Trough sitting SBP/DBP |
| Notes |
BP and SD of change not reported, endpoint BP reported, endpoint SD not reported, baseline SD not reported; imputed overall trial mean SBP/DBP SD of change; BP data from Table 2, p. 225; BP measurement device not reported; Jadad score=3; funding source= Takeda Euro R&D Centre |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
